Phosphodiesterase  	Phosphodiesterase  	 NNP	B-NP
Type  	Type  	 NNP	I-NP
5  	5  	 CD	O
Inhibitor  	Inhibitor  	 NNP	B-NP
Use  	Use  	 NNP	I-NP
Following  	Following  	 NNP	O
Radical  	Radical  	 NNP	B-NP
Prostatectomy  	Prostatectomy  	 NNP	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
Associated  	Associated  	 NNP	O
with  	with  	 IN	O
an  	an  	 DT	O
Increased  	Increased  	 JJ	B-NP
Risk  	Risk  	 NN	I-NP
of  	of  	 IN	I-NP
Biochemical  	Biochemical  	 NNP	I-NP
Recurrence  	Recurrence  	 NNP	I-NP
Recently 	Recently 	 NNP	O
,  	,  	 ,	O
conflicting  	conflicting  	 JJ	O
findings  	findings  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
reported  	reported  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
phosphodiesterase  	phosphodiesterase  	 JJ	B-NP
type  	type  	 NN	I-NP
5  	5  	 CD	I-NP
inhibitor  	inhibitor  	 NNS	I-NP
( 	( 	 -LRB-	O
PDE5I 	PDE5I 	 NNP	B-NP
)  	)  	 -RRB-	O
use  	use  	 NN	O
on  	on  	 IN	O
biochemical  	biochemical  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
following  	following  	 VBG	O
radical  	radical  	 JJ	B-NP
prostatectomy  	prostatectomy  	 NNS	I-NP
( 	( 	 -LRB-	O
RP 	RP 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
investigated  	investigated  	 VBD	O
the  	the  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
PDE5I  	PDE5I  	 CD	O
treatment  	treatment  	 NN	O
following  	following  	 VBG	O
RP 	RP 	 NNP	B-NP
,  	,  	 ,	O
including  	including  	 VBG	O
therapeutic  	therapeutic  	 JJ	B-NP
strategy 	strategy 	 NN	I-NP
,  	,  	 ,	O
timing 	timing 	 NN	O
,  	,  	 ,	O
duration 	duration 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
drug  	drug  	 NN	B-NP
type 	type 	 NN	I-NP
,  	,  	 ,	O
on  	on  	 IN	O
oncologic  	oncologic  	 JJ	B-NP
outcomes 	outcomes 	 NNS	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
analyzed  	analyzed  	 VBD	B-NP
records  	records  	 NNS	I-NP
of  	of  	 IN	O
1082  	1082  	 CD	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
underwent  	underwent  	 VBD	O
bilateral  	bilateral  	 JJ	B-NP
nerve-sparing  	nerve-sparing  	 JJ	I-NP
RP  	RP  	 NN	I-NP
for  	for  	 IN	O
clinically  	clinically  	 JJ	O
localized  	localized  	 JJ	O
prostate  	prostate  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
PCa 	PCa 	 NNP	B-NP
)  	)  	 -RRB-	O
between  	between  	 IN	O
2005  	2005  	 CD	O
and  	and  	 CC	O
2014 	2014 	 CD	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
were  	were  	 VBD	O
categorized  	categorized  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
PDE5I  	PDE5I  	 CD	O
use  	use  	 NN	O
within  	within  	 IN	O
2 years  	2 years  	 CD	O
following  	following  	 VBG	O
RP 	RP 	 NNP	B-NP
:  	:  	 :	O
non-user 	non-user 	 NN	B-NP
,  	,  	 ,	O
on-demand 	on-demand 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
rehabilitation  	rehabilitation  	 NN	B-NP
( 	( 	 -LRB-	O
daily  	daily  	 JJ	O
PDE5I  	PDE5I  	 CD	O
use  	use  	 NN	O
for  	for  	 IN	O
≥3 months 	≥3 months 	 CD	O
)  	)  	 -RRB-	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Associations  	Associations  	 NNS	B-NP
of  	of  	 IN	O
various  	various  	 JJ	O
factors  	factors  	 NNS	O
with  	with  	 IN	O
biochemical  	biochemical  	 JJ	B-NP
recurrence  	recurrence  	 NN	I-NP
( 	( 	 -LRB-	O
BCR 	BCR 	 NNP	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
analyzed  	analyzed  	 VBN	O
using  	using  	 VBG	O
a  	a  	 DT	O
Cox  	Cox  	 NNP	B-NP
multivariate  	multivariate  	 FW	I-NP
proportional  	proportional  	 FW	I-NP
hazards  	hazards  	 FW	I-NP
model 	model 	 NN	O
.  	.  	 .	O
Propensity  	Propensity  	 JJ	O
score-matched  	score-matched  	 JJ	O
analysis  	analysis  	 NN	O
was  	was  	 VBD	O
also  	also  	 RB	O
performed 	performed 	 VBN	O
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
subjects  	subjects  	 NNS	B-NP
included  	included  	 VBD	O
in  	in  	 IN	O
our  	our  	 PRP$	O
study 	study 	 NN	O
,  	,  	 ,	O
PDE5I  	PDE5I  	 CD	O
use  	use  	 NN	O
was  	was  	 VBD	O
as  	as  	 RB	O
follows 	follows 	 VBZ	O
:  	:  	 :	O
253  	253  	 CD	O
( 	( 	 -LRB-	O
23.4  	23.4  	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
non-users 	non-users 	 NNP	B-NP
,  	,  	 ,	O
475  	475  	 CD	O
( 	( 	 -LRB-	O
43.9  	43.9  	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
on-demand  	on-demand  	 JJ	B-NP
users 	users 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
354  	354  	 CD	O
( 	( 	 -LRB-	O
32.7  	32.7  	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
rehabilitation 	rehabilitation 	 NN	B-NP
.  	.  	 .	O
Multivariate  	Multivariate  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
showed  	showed  	 VBD	O
that  	that  	 IN	O
PDE5I  	PDE5I  	 CD	O
use  	use  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
factor  	factor  	 NN	B-NP
with  	with  	 IN	O
regard  	regard  	 NN	O
to  	to  	 TO	O
BCR  	BCR  	 NNP	B-NP
risk  	risk  	 NN	I-NP
[ 	[ 	 -LRB-	O
hazard  	hazard  	 NN	B-NP
ratio  	ratio  	 NN	I-NP
1.47  	1.47  	 CD	O
( 	( 	 -LRB-	O
0.765-2.826 	0.765-2.826 	 NNP	O
) 	) 	 -RRB-	O
;  	;  	 :	O
p = 0.248 	p = 0.248 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
PDE5I  	PDE5I  	 CD	O
users 	users 	 NNS	O
,  	,  	 ,	O
a  	a  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
PDE5I  	PDE5I  	 CD	O
use  	use  	 NN	O
( 	( 	 -LRB-	O
on-demand  	on-demand  	 FW	B-NP
vs.  	vs.  	 FW	O
rehabilitation 	rehabilitation 	 FW	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
timing  	timing  	 NN	O
of  	of  	 IN	O
initiating  	initiating  	 VBG	O
PDE5I  	PDE5I  	 CD	O
treatment  	treatment  	 NN	O
following  	following  	 VBG	O
RP 	RP 	 NNP	B-NP
,  	,  	 ,	O
duration  	duration  	 NN	O
of  	of  	 IN	O
PDE5I  	PDE5I  	 CD	O
use 	use 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
type  	type  	 NN	O
of  	of  	 IN	O
PDE5I  	PDE5I  	 NNP	O
used  	used  	 VBD	O
were  	were  	 VBD	O
not  	not  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
BCR  	BCR  	 NNP	B-NP
risk  	risk  	 NN	I-NP
in  	in  	 IN	O
multivariate  	multivariate  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
( 	( 	 -LRB-	O
p = 0.304 	p = 0.304 	 NNP	O
,  	,  	 ,	O
p = 0.177 	p = 0.177 	 NNP	O
,  	,  	 ,	O
p = 0.332 	p = 0.332 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
p = 0.105 	p = 0.105 	 NNP	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
PDE5I  	PDE5I  	 CD	O
use  	use  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
BCR  	BCR  	 NNP	B-NP
among  	among  	 IN	O
478  	478  	 CD	O
matched  	matched  	 CD	O
cohorts  	cohorts  	 NNS	O
( 	( 	 -LRB-	O
p = 0.672 	p = 0.672 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
PDE5I  	PDE5I  	 NNP	O
treatment  	treatment  	 NN	O
following  	following  	 VBG	O
RP  	RP  	 NNP	B-NP
was  	was  	 VBD	O
not  	not  	 RB	O
found  	found  	 VBN	O
to  	to  	 TO	O
have  	have  	 VB	O
any  	any  	 DT	O
significant  	significant  	 JJ	O
impact  	impact  	 NN	O
on  	on  	 IN	O
biochemical  	biochemical  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
regardless  	regardless  	 RB	O
of  	of  	 IN	O
therapeutic  	therapeutic  	 JJ	B-NP
strategy 	strategy 	 NN	I-NP
,  	,  	 ,	O
timing 	timing 	 NN	O
,  	,  	 ,	O
duration 	duration 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
drug  	drug  	 NN	B-NP
type 	type 	 NN	I-NP
.  	.  	 .	O
Such  	Such  	 JJ	O
findings  	findings  	 NNS	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
PDE5I  	PDE5I  	 CD	O
treatment  	treatment  	 NN	O
following  	following  	 VBG	O
RP  	RP  	 NNP	B-NP
is  	is  	 VBZ	O
oncologically  	oncologically  	 JJ	B-NP
safe 	safe 	 JJ	I-NP
.  	.  	 .	O
